Electromed, Inc. (ELMD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 32 | 36 | 42 | 48 | 55 | 64 | 74 | 74 |
| Operating profit | $m | 10 | 14 | ||||||
| Net profit | $m | 4 | 2 | 2 | 3 | 5 | 8 | 11 | 11 |
| EPS reported | $ | 0.86 | 1.31 | ||||||
| Operating cashflow per share | $ | 1.37 | 1.28 | ||||||
| Capex per share | $ | 0.04 | 0.04 | ||||||
| FCF per share | $ | 1.33 | 1.25 | ||||||
| Free cash flow | $m | 11 | 9 | ||||||
| Net debt | $m | -15 | -20 | ||||||
| Book value equity | $m | 43 | 54 | ||||||
| Book value per share | $ | 4.96 | 6.21 | ||||||
| Number of shares | m | 8.72 | 8.69 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 25.57 | 24.08 | ||||||
| P/B LTM | x | 4.24 | 3.40 | ||||||
| P/S LTM | x | 2.86 | 2.48 | ||||||
| P/FCF LTM | x | 16.53 | 19.81 | ||||||
| EV/EBITDA LTM | x | 14.68 | 10.99 | ||||||
| EV/Sales LTM | x | 2.63 | 4.52 | ||||||
| Earnings Yield LTM | % | +3.91% | +4.15% | ||||||
| FCF Yield | % | +6.05% | +5.05% | ||||||
| Quality | |||||||||
| ROE | % | +17.44% | +22.14% | ||||||
| ROIC | % | +16.67% | +20.11% | ||||||
| Operating margin | % | +15.43% | +18.55% | ||||||
| Gross margin | % | +78.08% | +78.44% | ||||||
| FCF/Sales | % | +17.32% | +14.25% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +48.28% | +125.86% | ||||||
| Sales Growth YoY | % | +16.97% | +34.83% | ||||||
| Net Income Growth YoY | % | +46.35% | +119.44% | ||||||
| FCF Growth | % | +27.85% | +6.68% | ||||||
| Operating Profit Growth | % | +50.01% | +110.93% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 55.99 | 69.56 | ||||||
| Net Debt/EBITDA | x | -1.32 | -1.14 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.35 | -0.38 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free